00:53 , Sep 15, 2018 |  BioCentury  |  Politics, Policy & Law

Debating diagnostics

Instead of perpetuating a decades-old dispute about whether FDA can and should regulate laboratory-derived tests, the agency and test makers have moved on to conversations about how FDA should do so, and from threats of...
18:54 , Jul 13, 2018 |  BC Week In Review  |  Financial News

With $132M series A, Compass points toward the clinic

Bispecific antibody play Compass Therapeutics LLC (Cambridge, Mass.) raised $49 million on July 12 in the final tranche of its series A round, bringing the round's total to $132 million. OrbiMed Advisers led the round. F-Prime...
15:35 , Jul 12, 2018 |  BC Extra  |  Financial News

With $132M series A, Compass points toward the clinic

Bispecific antibody play Compass Therapeutics LLC (Cambridge, Mass.) raised $49 million Thursday in the final tranche of its series A round, bringing the round's total to $132 million. OrbiMed Advisers led the round. F-Prime Capital Partners,...
13:48 , Apr 13, 2018 |  BC Week In Review  |  Company News

Alexandria LaunchLabs expanding to Cambridge, Mass.

Alexandria Real Estate Equities Inc. (NYSE:ARE) said it will expand Alexandria LaunchLabs to Cambridge, Mass. LaunchLabs is designed to provide life science start-ups with office space, equipment, amenities and access to investment capital. Last year, Alexandria...
04:19 , Apr 12, 2018 |  BC Extra  |  Financial News

Alexandria LaunchLabs expanding to Cambridge, Mass.

Alexandria Real Estate Equities Inc. (NYSE:ARE) said it will expand Alexandria LaunchLabs to Cambridge, Mass. LaunchLabs is designed to provide life science start-ups with office space, equipment, amenities and access to investment capital. Last year,...
18:52 , Mar 15, 2018 |  BC Innovations  |  Tools & Techniques

Shared burden

Having learned their lesson with PD-L1, companies are collaborating on assay standards for tumor mutation burden -- a likely contender for the next major biomarker in immuno-oncology. A Friends of Cancer Research-led consortium of pharmas...
16:03 , Mar 15, 2018 |  BC Extra  |  Company News

Arbor launches with $15.6 million, new CRISPR enzyme

Arbor Biotechnologies Inc. (Cambridge, Mass.) emerged from stealth mode on Thursday with a study detailing the discovery of a new CRISPR enzyme, CRISPR-associated protein 13d (Cas13d), and a $15.6 million series A round that closed...
16:38 , Jan 12, 2018 |  BC Week In Review  |  Financial News

Alexandria launches seed capital platform

Alexandria Venture Investments said on Jan. 7 it is continuing to boost its investment in early stage life science companies through the launch of the Alexandria Seed Capital Platform. Alexandria’s Jenna Foger told BioCentury the firm...
18:36 , Jan 11, 2018 |  BC Innovations  |  Emerging Company Profile

Next, after T cells

PD-1 pioneer Lieping Chen is solving some of the unanswered questions from that breakthrough with his new company, NextCure Inc. The idea is to use myeloid cell factors to boost the effectiveness of other T...
19:28 , Jan 8, 2018 |  BC Extra  |  Financial News

Alexandria launches seed capital platform

Alexandria Venture Investments said it is continuing to boost its investment in early stage life science companies through the launch of the Alexandria Seed Capital Platform. Alexandria’s Jenna Foger told BioCentury the firm saw a need...